Dr Matthew Lakelin is a co-founder of TrakCel. Using his knowledge in handling and distribution of CGTs he has assisted with the development of the technology platform and is passionate about democratising advanced therapies. Matthew is one of TrakCel’s industry experts who is tasked with insuring projects are delivered on time and in budget.
Matthew holds a PhD in Pharmacology and has over 20 years’ experience working in the pharmaceutical and biotechnology industry. Matthew has led the deployment of TrakCel’s software to a wide range of advanced therapies (including CAR-T, TILs, personalised immunotherapies, neoantigen cancer vaccines) and in his role as VP Scientific Affairs is a key spokesperson and responsible for ensuring that TrakCel solutions continue to evolve to meet industry needs.